The aim of this study was to investigate in patients with stable angina the effects on costs of frontline diagnostics by exercise-stress testing (ex-test) vs. coronary computed tomography angiography (CTA).
Introduction
In the European Union countries, coronary artery disease (CAD) is responsible for .600.000 deaths every year. 1 The associated annual costs have been estimated at E49 billion, which is equivalent to 2.5% of the EU's total health expenditures. 2 Therefore, the economic efficiency of cardiac diagnostic strategies is gaining increasing attention. For decades, ischaemia testing including exercise-stress testing (ex-test) has been recommended as the diagnostic gatekeeper in patients suspected of CAD. 3 In line with a tremendous evolution in computed tomography technology, non-invasive coronary computed tomography angiography (CTA) has emerged as a diagnostic alternative to conventional ischaemia testing in patients with a low to intermediate pre-test probability of CAD. 4 However, the use of CTA as a frontline diagnostic test in patients suspected of CAD has been questioned since CTA identifies more patients with atherosclerosis than conventional functional diagnostic methods, hence add the risk of introducing further unnecessary diagnostic and therapeutic procedures. 5 Therefore, the purpose of this study was to evaluate the effects on costs of a real-world frontline diagnostic strategy using either the ex-test or CTA in patients with stable angina and a low-to-intermediate pre-test likelihood of disease.
Methods Patients
Between January 2007 and February 2008, 1267 patients without known CAD consecutively referred (by general practitioners or noncardiology ambulatory clinics) for the evaluation of chest pain at the ambulatory clinics at two coronary units (Vejle and Fredericia, localized 30 km apart) at Lillebaelt Hospital, Denmark were retrospectively evaluated for inclusion in this study. Patients were referred to either of the two units based on strictly geographical considerations. Patients underwent an initial clinical evaluation by an experienced cardiovascular clinician. Until 2007 the preferred frontline diagnostic method at Lillebaelt Hospital for patients suspected of angina with a low to intermediate pre-test probability of CAD was the ex-test. In January 2007 the Vejle unit implemented CTA as the preferred frontline diagnostic test in such patients. The change in diagnostic strategy in only one of the Lillebaelt Hospital coronary units allowed us to compare the impact on costs of the two diagnostic strategies. High-risk patients at both units preferably were referred for invasive coronary angiography (ICA), whereas patients with a low or intermediate pre-test probability of CAD in whom the ex-test or CTA could not be performed (e.g. physical incapacity or renal insufficiency) preferably were referred for myocardial perfusion scintigraphy imaging (MPI) or ICA. There was no difference in the competence level or professional charge of the referring clinicians at the two units. After the initial clinical evaluation, 260 patients were discharged or referred for diagnostic evaluation of non-cardiac disease, 363 (Fredericia unit, n ¼ 164; Vejle unit, n ¼ 199) patients were referred for ICA, and 146 (Fredericia, n ¼ 89; Vejle, n ¼ 57) patients to MPI. Thus, 498 patients with suspected CAD were referred for either an initial ex-test (n ¼ 247) or CTA (n ¼ 251). The index diagnostic test date was defined as the date a patient underwent either of the two tests. Baseline demographics and patients' medical records were registered from electronic patient files. Patients were classified as having a low (,13.4%), intermediate, or high (.87.2%) pre-test probability of CAD according to the original Diamond -Forrester algorithm 6 . Symptoms were categorized as nonanginal, atypical, or typical angina. 7 The study was approved by the Danish Data Protection Agency (Journal Number, 2009-413523) with a waiver for individual informed consent by the Regional Ethical Committee.
Exercise-stress testing
The ex-test was performed using a national standardized protocol. 8 In the latter protocol, cessation of beta-blockers is recommended prior to an ex-test. The test was considered positive in the presence of ≥0.1 mV horizontal or descending ST depression measured 80 ms from the J-point, ventricular arrhythmia during or after exercise, a systolic blood pressure drop ≥20 mmHg during exercise, or if the patient developed angina pectoris. The test was considered inconclusive in the absence of the above-mentioned criteria without reaching 85% of the age-adjusted target heart rate. The ex-tests were performed by physicians with knowledge of all relevant patient information. Before test conclusions were reached, ex-test examinations were reviewed by an experienced cardiologist.
Coronary computed tomography angiography
A standard protocol for image acquisition at a 64-slice Dual Source CT system (Siemens Definition, Siemens Medical Solution, Forcheim, Germany) was applied. 9 Contraindications to CTA were pregnancy, renal insufficiency, or known allergy to iodinated contrast. Assessment of CTA was performed using axial source images and multi-planar reconstructions. The CTA result was defined as positive in the presence of at least one atherosclerotic lesion causing ≥50% luminal narrowing and negative in the absence of a significant coronary artery lesion. The CTA evaluation and conclusions were made by cardiologists with knowledge of all relevant patient information. Extra-cardiac analysis was performed in all patients by experienced radiologists.
Post-test management of patients
All test results were reviewed by experienced cardiac clinicians before post-test management. Post-test management of patients were at the discretion of the referring clinicians, however, according to internal guidelines at the department of cardiology, Lillebaelt Hospital during the study period, ICA was recommended in symptomatic patients with a positive index test result, whereas no further testing was recommended in those with a normal test result. Patients with an equivocal index test result were managed at the discretion of the referring physician. Patients with extra-cardiac findings were managed at the discretion of the reading CTA physician after reviewing the case with other specialists.
Follow-up
Patients were followed for 12 months after the index test. The occurrence of major adverse events including cardiac death and non-fatal myocardial infarction International Statistical Classification of Diseases and Related Health Problems, 10th Revision [ICD-10] codes D121, DI210, DI210B, DI219, DI252 were registered during the follow-up. In addition, data on cardiac downstream test utilization, cardiovascular medication, coronary revascularization (percutaneous coronary intervention, coronary bypass graft surgery), and hospitalizations for unstable angina (ICD-10 codes DI200, DI200B+C) or stable angina (ICD-10 codes DI201, DI208-9, DI251, DI251B+C), hospitalizations on suspicion of CAD (ICD-10 codes DR079, DZ034), and ambulatory visits on a suspicion of CAD (ICD-10 codes DI200, DI200B+C, DI201, DI208-9, DI251, DI251B+C, DR079, DZ034), respectively, together with data (DTU and treatment) associated with extra-cardiac findings during the follow-up period were registered. Data were derived from the Danish National Patient Registry, the West-Danish Heart Registry, and the University of Southern Denmark Pharmacoepidemiological Database.
Radiation dose
The dose-length product (DLP) of CTA was derived from patient files. The effective radiation dose was derived as the product of DLP and an organ weighting factor (0.014) for the chest in adults. 10 Information on the radiation dose related to ICA and MPI was obtained from patient files and the West-Danish Heart Registry.
Statistical analysis
Continuous variables are expressed as means (standard deviations, SD) and medians (ranges) as appropriate. Continuous variables were compared using Student's t-test (for normally distributed variables) or the
Mann-Whitney U test (for variables not normally distributed). All costs were expressed in 2007 Euros (EUR). Cost estimations were based on diagnosis-related group charges, charges for outpatient contacts, and pharmacy retail prices. Total costs were calculated as the sum of cardiac DTU, cardiovascular medication, coronary revascularizations, hospitalizations, and costs associated with ambulatory consultations during follow-up. A secondary analysis including costs associated with extra-cardiac findings (DTU and treatment) was performed. The cumulative total costs were computed at 1, 6, and 12 months after the index diagnostic test. Comparison of cost data in the ex-test and CTA groups were performed adjusting for the pre-test probability of CAD and the index test result (positive vs. negative), respectively. Regression analysis was performed in order to adjust cost estimates from differences in the pre-test probability of CAD and other baseline covariates. A substantial number of patients incurred no downstream costs and therefore a two-part model was applied. 11 In this analysis the probability that the patient had zero or non-zero costs is predicted in the first part. First logistic regression analysis was applied in order to estimate the probability that the patient had zero or non-zero costs. In the second part of the model, the level of cost conditional upon having positive costs was predicted. We applied a generalized linear regression model (GLM), applying a log link function and assuming an inverse Gaussian distribution. Besides the test dummy variable 'ex-test yes/no' covariates in the GLM included the pre-test probability of CAD. The estimated costs are derived by multiplying the predictions from the two components (part 1 and 2) together. Cost analyses were performed using SAS (SAS Institute, Inc., Cary, NC, USA) software; otherwise the SPSS version 17.0 (SPSS, Chicago, USA) was applied. A significance level of 0.05 (twosided) was considered statistically significant.
Results
Information on baseline demographics, pre-test probability of CAD, and medications are presented in Effects on costs of frontline testing for angina 0.004). The ex-test was inconclusive due to inadequate exercise capacity in 7% of the patients, whereas CTA was inconclusive in 11% (P ¼ 0.14) due to motion artefacts (n ¼ 19), extensive coronary calcification (n ¼ 8), or technical reasons (n ¼ 1).
Downstream test utilization and treatment
Data on DTU previously have been reported. 12 In brief, rates of cardiac DTU were higher among patients in the ex-test compared with the CTA group, 36 vs. 22% (P ¼ 0.001). The mode of cardiac DTU according to the index test result is shown in Table 2 . In patients with an inconclusive test result DTU was applied in 93% in the CTA vs. 33% in the ex-test group (P , 0.001). In patients with a positive index test result, 34% in the ex-test group had significant CAD at subsequent ICA (.50% narrowing of the lumen in at least one vessel) compared with 65% in the CTA group (P ¼ 0.02). No difference was observed in the frequency of coronary revascularizations between the two groups. More patients in the ex-test compared with the CTA group had anti-platelet agents or any anti-anginal medication prescribed after the index test. Additional testing was performed in 11 (4 chest X-rays, 7 chest CT scans, 1 mammography, 1 transoesophageal echcocardiography, 1 pulmonary scintigraphy, and 3 hepatic ultrasonographies) out of 44 patients in the CTA group with one or more extracardiac findings. Subsequently, in two patients malignancies were diagnosed and treated (one breast lumpectomy with adjuvant radiotherapy and one lung lobectomy).
Cardiac ambulatory contacts and hospitalizations
No difference was observed between index test groups in the proportion of patients with ≥1 ambulatory contacts on a suspicion of angina, 27% in the ex-test group vs. 21% in the CTA group (P ¼ 0.14), or in the proportion of patients with ≥1 downstream CAD-related hospitalizations during follow-up, 6% in both groups.
Cost analysis
Mean (SD) total costs per patient after 1 year of follow-up were higher in the ex-test group compared with the CTA group, E1777 (3746) vs. E1510 (3974) (P ¼ 0.03). Including information on extra-cardiac findings (DTU and treatment) increased mean (SD) CTA-associated expenses to E1603 (4111) (P ¼ 0.05 when comparing with costs in the ex-test group). The cumulated downstream costs during 12 months of follow-up are shown in Figure 1 , and the cumulated costs according to the index test result are shown in Figure 2 . Mean total costs per patient in relation to the index test result and pre-test probability of CAD levels are presented in Table 3 . Relative costs associated with cardiac DTU, cardiovascular medication, coronary revascularizations, hospitalizations, and ambulatory visits, respectively, are illustrated in Figure 3 . Mean costs associated with DTU, cardiac ambulatory visits, cardiovascular medication, coronary revascularizations, and hospitalizations at 12 months are shown in 
Clinical follow-up
No patients from the two groups died within the follow-up period.
In the ex-test group three patients (all with a negative index test result) suffered an acute myocardial infarction after 6, 8, and 12 months, respectively. Both patients with malignancy as detected by the extra-cardiac analysis were free of disease after 12 months.
Radiation dose
The mean (SD) radiation dose of CTA, ICA, or MPI was 7.5 (3.6), 5.4 (2.9), and 7.5 (2.4) mSv, respectively. The total mean (SD) procedural radiation dose summating the dose from the index and cardiac downstream diagnostic procedures was higher in the CTA compared with the ex-test group, 9.0 (3.7) vs. 2.1 (3.7) mSv (P , 0.001). The total mean (SD) radiation dose from downstream diagnostic procedures in the index test negative groups was higher in the ex-test compared with the CTA group, 0. 
Discussion
Diagnosis and treatment costs of CAD consume a large amount of health-care resources. 2 Cardiac imaging is a major contributor to the rising health-care costs with a growth rate of 25% annually in both the EU and the USA. 13 Thus, the economic efficiency of medical diagnostic strategies from the perspective of society is increasingly important.
Guidelines on the management of stable angina from the European Society of Cardiology still recommend the ex-test as the appropriate frontline non-invasive diagnostic test. 3 Coronary CTA has been proposed as an alternative non-invasive diagnostic modality in patients suspected of CAD, and numerous studies have shown a notably high diagnostic accuracy of CTA in patients with stable angina. 4 Recent studies in patients suspected of CAD indicate higher diagnostic performance of CTA in comparison with ex-test. 9 However, the higher diagnostic accuracy of CTA Effects on costs of frontline testing for angina cost outcomes unless the test result influences physician or patient behaviour. This study of symptomatic patients with a low-intermediate pre-test likelihood of CAD indicates that the inferior diagnostic performance of the ex-test relative to CTA is associated with an overall reduction in downstream health-care costs by 14%. In this study post-test cardiovascular medication-related costs were 22% higher in the ex-test compared with the CTA group. Nonobstructive CAD may be revealed by CTA and result in a more selective post-test medication strategy, e.g. patients at an intermediate pre-test risk of CAD may avoid cardiovascular preventive medication in the event of a normal test result. When including information on extra-cardiac findings, the favourable cost profile of a CTA vs. ex-test diagnostic strategy in this study was of borderline significance only. The issue on extra-cardiac analysis in CTA is somewhat controversial; hence it has been suggested that such a strategy merely results in additional costs and morbidity without a clear benefit on mortality.
14 As opposed to the latter statement, others including our institution believe in an ethical obligation to review the entire CTA data set. However, important issues, i.e. on long-term follow-up, life expectancy, quality of life, and job absenteeism, were not included in this and other studies; thus the cost-effectiveness of extra-cardiac analysis in CTA needs further delineation in future studies. The influence of CTA in the outpatient setting among patients suspected of CAD on subsequent diagnostic testing, costs, and clinical outcomes has been investigated in a few studies. 15 -17 In a decision analytic model, Dewey et al. 15 demonstrated a 17% reduction in costs per correctly identified patient with CAD (with a 10 -50% pre-test likelihood of CAD) by using CTA rather than the ex-test or stress echocardiography studies. In an observational study based on a private insurance claims database, Min et al. 16 demonstrated a 12-month 26% reduction in total CAD-related costs in individuals without known CAD (mean age, 57 years) following initial diagnostic testing by CTA rather than MPI. A recent retrospective study by Shreibati et al. 17 of Medicare beneficiaries compared DTU and associated costs following stress testing and CTA. At 6 months of follow-up, CAD-related costs were nearly twice as high in patients diagnosed by CTA as in those in whom the ex-test were performed. The average age in the study by Shreibati et al. was 74 years (compared with 56 years in the present study), and more patients had diabetes, hypertension, and hyperlipidaemia compared with the present study cohort. As the pre-test risk of anatomical CAD is positively associated with the burden of coronary calcification, and inversely correlated to the diagnostic specificity of CTA, 18 subsequent increasing DTU and costs must be anticipated in patients at a high risk of CAD. Thus, the conflicting outcome between the study by Shreibati et al. and the present one may at least partially be explained by differences in the pre-test risk of CAD. The present study differs from and is additive to the prior literature in that it, in a 'real-world' setting, examined the influence of patient-level differences (i.e. with regard to the index diagnostic test outcome and the pre-test likelihood of CAD) on costs.
The cost efficiency of a diagnostic test necessitates in addition to documentation of lower costs also equivalent or improved clinical outcomes. In a recent study by Dedic et al. 19 on CTA of anginal patients, CTA was more efficient than the ex-test in predicting subsequent serious cardiac events. In the aforementioned studies by Min and Shreibati, however, there was no significant difference in the frequency of serious cardiac events during follow-up. In this study all adverse cardiac events during followup occurred in the ex-test result negative group. However, the incidence of cardiac events in this study was very low; hence with regard to the safety of the two diagnostic strategies, conclusions should be drawn with caution. The safety of frontline CTA vs. ischaemia testing needs further investigation in future prospective studies. During the study period ischaemia testing was not performed routinely prior to coronary revascularization in Denmark. Given the limited accuracy of CTA in stenosis quantification 20 , it may be speculated that a higher stenosis cut-point or additional detailed lesion specific myocardial ischaemia testing such as MPI or fractional flow reserve (FFR) may reduce the proportion of unnecessary ICAs or coronary revascularizations following CTA and thus costs. In concordance with the latter hypothesis is the fact that an FFR-guided coronary revascularization strategy in patients with multivessel disease seems to be cost-effective. 21 Because of the radiation exposure associated to CTA, there is much scrutiny on the increasing clinical use of this method. 22 The radiation dose of the diagnostic modalities used in this study was comparable with previous findings. 22 Although the cumulated associated effective radiation dose was consistently higher in patients undergoing CTA compared with the ex-test, it should be acknowledged that the ex-test in selected patients was associated to a subsequent non-negligible radiation exposure. Awareness of radiation use by physicians combined with technical improvements, including ECG-triggered tube modulation for spiral scan modes, prospectively triggered sequential scan protocols, and the use of lower voltage in smaller sized patients have brought down the daily average CTA radiation dose below 5 mSv. 23 Moreover, high-pitch spiral CT with an effective dose 
Limitations
The inherent limitations of the observational and retrospective design of this study must be acknowledged. Although the two study populations were identical with regard to baseline characteristics (except for a more frequent use of nitrates in the ex-test group) and the pre-test probability of CAD, a bias towards the use of one rather than the other diagnostic strategy in certain patient groups (e.g. physical incapacity or renal insufficiency) cannot be excluded. The differences in DTU between groups could reflect differences in operator skills rather than being test related. However, all ex-test results were reviewed by experienced cardiac clinicians before further action was taken. Moreover, patient post-test management in this report reflects contemporary clinical practice without the introduction of rigorous criteria on post-test management. With respect to the study size, a dichotomous definition of the test results was used. However, the latter strategy provided a more valid comparison for estimating differences in downstream CAD-related costs and clinical outcomes. Of note, a high proportion of patients in this study were, at the discretion of the treating physician, adjudicated as having 'non-anginal' chest pain. However, based on their total risk profile including sex and age, most of the patients ( 70%) had a pre-test intermediate risk of CAD, and thus fulfilled guidelines with regard to the relevance of further diagnostic testing. 3 This study was performed from a health payer perspective, and indirect costs associated with job absenteeism were not included. The outcomes of the present study were restricted to 1 year. Overall, the findings in the present study need confirmation in larger prospective trials. The ongoing randomized PROspective Multicenter Imaging for Evaluation of Chest Pain (PROMISE) trial investigates the influence over 2-year follow-up of an initial anatomical diagnostic strategy using CTA vs. initial stress testing on, e.g. medical costs and clinical outcomes in patients suspected of CAD. 25 
Conclusion
In symptomatic patients with a low-intermediate probability of CAD a frontline diagnostic strategy using CTA in comparison with ex-test incurred lower costs. Future prospective studies are needed in order to delineate further the consequences on costs and safety of frontline CTA vs. ischaemia testing. Conflict of interest: none declared.
